© The Author 2006. Published by Oxford University Press.
ARTICLE |
Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer
Affiliations of authors: Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, Boston, MA (MJH, CCE); Department of Health Care Policy, Harvard Medical School, Boston, MA (AJO, JRP, JPN)
Correspondence to: Michael J. Hassett, MD, MPH, Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, 44 Binney Street, 454-STE 21, Boston, MA 02115-6084 (e-mail: mhassett{at}partners.org).
Background: The number, nature, and costs of serious adverse effects experienced by younger women receiving chemotherapy for breast cancer outside of clinical trials are unknown. Methods: From a database of medical claims made by individuals with employer-provided health insurance between January 1998 and December 2002, we identified 12 239 women 63 years of age or younger with newly diagnosed breast cancer, of whom 4075 received chemotherapy during the 12 months after the initial breast cancer diagnosis and 8164 did not. Diagnostic codes for eight chemotherapy-related adverse effects were identified. Total hospitalizations for all causes, hospitalizations or emergency room visits for adverse effects that are typically related to chemotherapy, and health care expenditures were compared between the two groups of women. All statistical tests were two-sided. Results: Women who received chemotherapy were more likely than those who did not to be hospitalized or to visit the emergency room for all causes (61% versus 42%; mean difference = 19%, 95% confidence interval [CI] = 16.7% to 21.3%, P<.001) and for chemotherapy-related serious adverse effects (16% versus 5%, mean difference = 11%, 95% CI = 9.6% to 12.4%, P<.001). The percentages of chemotherapy recipients who were hospitalized or visited the emergency room during the year after their breast cancer diagnosis were 8.4% for fever or infection; 5.5% for neutropenia or thrombocytopenia; 2.5% for dehydration or electrolyte disorders; 2.4% for nausea, emesis, or diarrhea; 2.2% for anemia; 2% for constitutional symptoms; 1.2% for deep venous thrombosis or pulmonary embolus; and 0.9% for malnutrition. Chemotherapy recipients incurred large incremental expenditures for chemotherapy-related serious adverse effects ($1271 per person per year) and ambulatory encounters ($17 617 per person per year). Conclusions: Chemotherapy-related serious adverse effects among younger, commercially insured women with breast cancer may be more common than reported by large clinical trials and lead to more patient suffering and health care expenditures than previously estimated.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer
- Antonio Russo, Mariangela Autelitano, and Luigi Bisanti
J Natl Cancer Inst 2006 98: 1826-1827.[Extract] [Full Text] [PDF]
Editorial about this Article
- On the Toxicity of Chemotherapy for Breast Cancer—the Need for Vigilance
- John K. Erban and Joseph Lau
J Natl Cancer Inst 2006 98: 1096-1097.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  K. Lang, M. Sussman, M. Friedman, J. Su, H. J. Kan, D. Mauro, E. Tafesse, and J. Menzin Incidence and Costs of Treatment-Related Complications Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Arch Otolaryngol Head Neck Surg, June 1, 2009; 135(6): 582 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Azzone, R. G. Frank, J. R. Pakes, C. C. Earle, and M. J. Hassett Behavioral Health Services for Women Who Have Breast Cancer J. Clin. Oncol., February 10, 2009; 27(5): 706 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Setoguchi, C. C. Earle, R. Glynn, M. Stedman, J. M. Polinski, C. P. Corcoran, and J. S. Haas Comparison of Prospective and Retrospective Indicators of the Quality of End-of-Life Cancer Care J. Clin. Oncol., December 10, 2008; 26(35): 5671 - 5678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Duffy and J. Crown A Personalized Approach to Cancer Treatment: How Biomarkers Can Help Clin. Chem., November 1, 2008; 54(11): 1770 - 1779. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Li, M.-F. Penet, P. Winnard Jr., D. Artemov, and Z. M. Bhujwalla Image-Guided Enzyme/Prodrug Cancer Therapy Clin. Cancer Res., January 15, 2008; 14(2): 515 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Mori, K. Glunde, T. Takagi, V. Raman, and Z. M. Bhujwalla Choline Kinase Down-regulation Increases the Effect of 5-Fluorouracil in Breast Cancer Cells Cancer Res., December 1, 2007; 67(23): 11284 - 11290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Kuderer, D. C. Dale, J. Crawford, and G. H. Lyman Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic Review J. Clin. Oncol., July 20, 2007; 25(21): 3158 - 3167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E. Felman Impact of Toxicity Assumptions on Socioeconomic Analysis of Breast Cancer Chemotherapy J. Clin. Oncol., June 1, 2007; 25(16): 2331 - 2332. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Russo, M. Autelitano, and L. Bisanti Re: Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer J Natl Cancer Inst, December 20, 2006; 98(24): 1826 - 1827. [Full Text] [PDF]
|
|
|
|
 |
|
 Morbidity from Breast Cancer Chemo -- Greater Than Expected? Journal Watch Women's Health, October 26, 2006; 2006(1026): 2 - 2. [Full Text]
|
|
|
|
|
|
J. K. Erban and J. Lau On the Toxicity of Chemotherapy for Breast Cancer--the Need for Vigilance. J Natl Cancer Inst, August 16, 2006; 98(16): 1096 - 1097. [Full Text] [PDF]
|
|